Coeptis Therapeutics Holdings Overview
Valuation check: COEP's ROE is -52.18%, below the sector sector average of -4.03%.
Get informed when a big investor buys or sells
+ Follow-52.18%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Coeptis Therapeutics Holdings (COEP) currently reports a ROE of -52.18%. That is below the sector sector average of -4.03%. Use the charts on this page to explore Coeptis Therapeutics Holdings's ROE history and peer comparisons.
Coeptis Therapeutics Holdings's ROE of -52.18% is lower than the its sector sector average of -4.03%. That is roughly 1196.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Coeptis Therapeutics Holdings's current -52.18% should be judged against industry norms (sector average: -4.03%) and against COEP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -52.18%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -4.03%. From there, open related valuation or income-statement pages for Coeptis Therapeutics Holdings, and consider following COEP for alerts when major investors trade the stock.
